Related Experiment Video
Updated: Jan 19, 2026

Measuring Microbial Mutation Rates with the Fluctuation Assay
Published on: November 28, 2019
A 40-YEAR FOLLOW-UP OF A PATIENT WITH MULTIPLE PARAGANGLIOMAS AND A SDHD MUTATION
A Elenkova1, R Robeva1, A P Gimenez-Roqueplo2,3
1Medical University of Sofia Faculty of Medicine - Department of Endocrinology, USHATE "Acad. Ivan Penchev", Sofia, Bulgaria.
Context:
Germline mutations in Succinate Dehydrogenase Complex Subunit D gene (SDHD) predispose to predominantly benign head and neck and/or thoracic-abdominal pelvic paragangliomas (PGLs).
Objective:
We present the case of a patient carrying a germline SDHD mutation responsible for multiple PGLs, who was followed for 40 years. He was initially diagnosed with a left cervical PGL at the age of 23 years, treated by surgery. Then, he recurred and developed a multifocal disease. The second-line therapeutic option was a three-dimensional conformal radiotherapy performed in 2008. In 2013 the patient had clinical, hormonal, PET- and SPECT-CT data revealing a disease progression. The treatment with the long-acting somatostatin analogue Octreotide Lar was carried out till the patient's death caused by pulmonary embolism in December 2014.
Results:
Complex treatment led to a long clinical and biochemical remission and control of tumor growth.
Conclusions:
Despite their usually benign behavior, multicentric SDHD-related PGLs can require a multimodal approach involving surgery, radiotherapy and medical treatment for providing a long-term control of the disease and maintaining a good quality of life.
Related Concept Videos
07:44Measuring Microbial Mutation Rates with the Fluctuation Assay
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Mutations
08:57Aip1p Dynamics Are Altered by the R256H Mutation in Actin
13:57Assessing the Multiple Dimensions of Engagement to Characterize Learning: A Neurophysiological Perspective
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

